BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35716369)

  • 41. An independently validated survival nomogram for lower-grade glioma.
    Gittleman H; Sloan AE; Barnholtz-Sloan JS
    Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
    Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
    Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas
    Huang X; Zhang F; He D; Ji X; Gao J; Liu W; Wang Y; Liu Q; Xin T
    Front Oncol; 2021; 11():646060. PubMed ID: 34094933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma.
    Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X
    PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
    Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
    BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
    White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
    Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Noor H; Zaman A; Teo C; Sughrue ME
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors.
    Lai G; Li K; Deng J; Liu H; Xie B; Zhong X
    J Healthc Eng; 2022; 2022():8704127. PubMed ID: 35535221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of molecular subtypes and a risk model based on inflammation-related genes in patients with low grade glioma.
    Long C; Song Y; Pan Y; Wu C
    Heliyon; 2023 Dec; 9(12):e22429. PubMed ID: 38046156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).
    Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X
    Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
    Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
    Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
    BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.